Amarantus Bioscience Holdings Inc (AMBS)

[newflow]

ZACKS PRICE TARGET $5 ON 11/25
Current Recommendation Buy
Prior Recommendation Sell
Date of Last Change 07/12/2015
Current Price (11/24/15) $0.35
Target Price $5.00
UPDATE:
Despite what we believe is aggressive discounting and
downward adjusting of our models based on overly
pessimistic probability assumptions, we are still arriving at a
target price of $5.00 per share. The current market
capitalization is only $4 million. Our target is far more
consistent with that we see as a peer-valuation for similarstage
NASDAQ listed companies. We believe several pending
catalysts over the next 15 months, including the AMDX sales /
spin-off, starting human clinical trials with MANF, reporting
results from the eltoprazine Phase IIb data, and the ESS
Phase IIa data should allow for the realization of a significantly
higher stock price.
http://www.otcmarkets.com/stock/AMBS/research